Evertz earned $19.09-million, or $.26 cents a share compared to $.22 last year. Management said it saw the biggest gains in the US/Canada region, where revenue was up 30% over last year.
The Burlington-based broadcast infrastructure company also announced that it will continue to pay a dividend of $0.14 per share. The board had raised it from $.12 a share in March.
The dividend is payable to shareholders of record on December 14, 2012 and will be paid on or about December 21, 2012.
Dieter Evertz founded his eponymous company in 1966, before selling to a group that included current bosses Romolo Margarelli and Doug DeBruin, who came over from Leitch Technologies. The Company went public in 2006, raising $67 million in a TSX IPO.
Evertz remains as one of the last public companies standing from a once robust Canadian broadcasting technology sector. The company’s fiscal 2012 revenue of $293.4-million came from a product line that includes timecode equipment, closed captioning technology and multiviewers. Evertz’s products have been used in the production of Star Wars III, Rocky 6, CSI, Oprah and the 2008 Olympics.
Shares of Evertz closed today down .2% to $16.22.
_______________
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and $130.00 target on Graham Corporation (Graham Corporation Stock Quote, Chart,… [Read More]
Beacon Securities analyst Doug Cooper says iFabric’s (iFabric Stock Quote, Chart, News, Analysts, Financials TSX:IFA) medical scrubs opportunity is being… [Read More]
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and street-high $88.00 target on MDA Space (MDA Space Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu raised his target on Hammond Power Solutions (Hammond Power Solutions Stock Quote, Chart, News,… [Read More]
RBC senior economist Claire Fan says Canada’s September job losses were concentrated among younger workers and should not be overread.… [Read More]
Roth Capital Partners analyst Adam Walsh says a third controlled celiac disease dataset supporting IL-15 blockade increases the potential value… [Read More]